MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 585095 | Name: Revizinone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Revizinone, also known as R 80123, inhibits cyclic nucleotide phosphodiesterase type III.

Chemical Structure

Revizinone
Revizinone
CAS#133718-29-3

Theoretical Analysis

MedKoo Cat#: 585095

Name: Revizinone

CAS#: 133718-29-3

Chemical Formula: C26H29N5O3

Exact Mass: 459.2270

Molecular Weight: 459.55

Elemental Analysis: C, 67.95; H, 6.36; N, 15.24; O, 10.44

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
R 80123; R80123; R-80123
IUPAC/Chemical Name
Acetamide, N-cyclohexyl-N-methyl-2-(((phenyl(1,2,3,5-tetrahydro-2-oxoimidazo(2,1-b)quinazolin-7-yl)methylene)amino)oxy)-, (E)-
InChi Key
VHDUUXNHZLBGHQ-XLVZBRSZSA-N
InChi Code
InChI=1S/C26H29N5O3/c1-30(21-10-6-3-7-11-21)24(33)17-34-29-25(18-8-4-2-5-9-18)19-12-13-22-20(14-19)15-31-16-23(32)28-26(31)27-22/h2,4-5,8-9,12-14,21H,3,6-7,10-11,15-17H2,1H3,(H,27,28,32)/b29-25+
SMILES Code
O=C(N(C1CCCCC1)C)CO/N=C(C2=CC=CC=C2)/C3=CC4=C(N=C(NC(C5)=O)N5C4)C=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 459.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Vroom MB, van Wezel HB, Visser CA, Eijsman L, van Zwieten PA. Hemodynamic effects of the novel selective cAMP-phosphodiesterase III inhibitor R 80122 in anesthetized patients with moderate left ventricular dysfunction before coronary artery bypass grafting. J Cardiothorac Vasc Anesth. 1995 Jun;9(3):272-7. PubMed PMID: 7669959. 2: Kazmaier S, Stephan H, Sonntag H. [Hemodynamic effects of new phosphodiesterase inhibitors in patients with coronary heart disease. A comparison between enoximone and R80122]. Anaesthesist. 1995 Jun;44(6):410-6. German. PubMed PMID: 7653792. 3: Stephan H, Kazmaier S, Hoeft A, Sonntag H. Effects of enoximone and R 80122, a new selective phosphodiesterase III inhibitor, on hemodynamics and myocardial energetics in patients with ischemic heart disease. Anesth Analg. 1994 Dec;79(6):1059-65. PubMed PMID: 7978427. 4: Autschbach R, Lange H, Stephan H, Mohr FW, Becker B, Sonntag H. Effects of R80122, a new phosphodiesterase inhibitor, on liver and global haemodynamics in patients undergoing coronary artery bypass surgery. Cardiovasc Surg. 1994 Dec;2(6):698-702. PubMed PMID: 7858987. 5: Schröder T, Hering JP, Foth H, Ferrari M, Sipinková I, Hellige G. Peripheral and cardiac effects of a new phosphodiesterase inhibitor in comparison with enoximone. Arzneimittelforschung. 1994 Aug;44(8):948-50. PubMed PMID: 7945538. 6: Herregods L, Rolly G, Van Belleghem Y, Van Nooten G. Haemodynamic effects of R 80122 immediately after cardiopulmonary bypass; preliminary results. Anaesthesia. 1994 Aug;49(8):719-22. PubMed PMID: 7943708. 7: Li Q, Himmel HM, Ravens U. Effects of the new phosphodiesterase-III inhibitor R80122 on contractility and calcium current in human cardiac tissue. J Cardiovasc Pharmacol. 1994 Jul;24(1):133-43. PubMed PMID: 7521478. 8: Roevens P, de Chaffoy de Courcelles D. Cyclic AMP-phosphodiesterase IIIA1 inhibitors decrease cytosolic Ca2+ concentration and increase the Ca2+ content of intracellular storage sites in human platelets. Biochem Pharmacol. 1993 Jun 9;45(11):2279-82. PubMed PMID: 8390836. 9: Schneider J, Beck E, Heers C, Conrad C, de Chaffoy de Courcelles D, Wilffert B, Peters T. Cardiac effects of R 79595 and its isomers (R 80122 and R 80123) in an acute heart failure model. A new class of cardiotonic agents with highly selective phosphodiesterase III inhibitory properties. Naunyn Schmiedebergs Arch Pharmacol. 1992 Nov;346(5):563-72. PubMed PMID: 1470228. 10: de Cheffoy de Courcelles D, de Loore K, Freyne E, Janssen PA. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds. J Pharmacol Exp Ther. 1992 Oct;263(1):6-14. PubMed PMID: 1328613. 11: Lange H, Stephan H, Autschbach R, Lueerssen K, Zielmann S, Sonntag H. [Effects of R80122. The influence of a new phosphodiesterase inhibitor on global and intestinal hemodynamics in coronary surgery patients]. Anaesthesist. 1992 Aug;41(8):474-80. German. PubMed PMID: 1524159. 12: Van de Water A, Xhonneux R, Reneman RS, Janssen PA. Cardiac and hemodynamic effects of intravenous R80122, a new phosphodiesterase III inhibitor, in a canine model of myocardial ischemia and heart failure. J Cardiovasc Pharmacol. 1992 Jul;20(1):18-24. PubMed PMID: 1383627. 13: Vandeplassche GM, Hermans CF, de Chaffoy de Courcelles DR, D'Aubioul JA, Wouters LJ, De Clerck FF. Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs. J Cardiovasc Pharmacol. 1992 May;19(5):714-22. PubMed PMID: 1381769. 14: Van de Water A, d'Aubioul J, Van Gerven W, de Chaffoy de Courcelles D, Freyne E, Xhonneux R, Reneman RS, Janssen PA. Cardiac and hemodynamic effects of intravenous R 80122, a new phosphodiesterase III inhibitor, in anesthetized and awake dogs. Arch Int Pharmacodyn Ther. 1992 Mar-Apr;316:60-74. PubMed PMID: 1530374. 15: Wilhelm D, Wilffert B, Janssens WJ, Leidig A, Meuter C, Ebbert M, Peters T. In vitro pharmacology of R 80122, a novel phosphodiesterase inhibitor. J Cardiovasc Pharmacol. 1992;20(5):705-14. PubMed PMID: 1280731.

View History

Desethylchloroquine HCl

Desethylchloroquine HCl